Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.37 |
| ▸ | PDE4A | P27815 | 14/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26247632 | 0.74 | PDE4B (0.38) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL26782657 | 0.73 | PDE4B (0.38) | PDE4BPDE4APDE4CPDE4DCHRM3 | |
| SCHEMBL30536723 | 0.73 | PDE4B (0.55) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL30305943 | 0.73 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL24195516 | 0.73 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL24194272 | 0.73 | PDE4B (0.55) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL26783597 | 0.71 | PDE4B (0.38) | PDE4BPDE4APDE4CPDE4DCHRM3 | |
| SCHEMBL24188789 | 0.70 | PDE4B (0.41) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL25383400 | 0.69 | PDE4B (0.40) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL30536728 | 0.69 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | CNR1, CNR2, SIGMAR1 | PDE4B 4688/4885PDE4A 4791/4885PDE4C 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.